Antonia J. Lewis

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

The effect of bariatric surgery type on cardiac reverse remodelling.

The effect of bariatric surgery type on cardiac reverse remodelling.

Journal: International journal of obesity (2005)

Published: July 25, 2023

Changes in epicardial and visceral adipose tissue depots following bariatric surgery and their effect on cardiac geometry.

Changes in epicardial and visceral adipose tissue depots following bariatric surgery and their effect on cardiac geometry.

Journal: Frontiers in endocrinology

Published: November 08, 2022

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.

Journal: Journal of medicinal chemistry

Published: August 13, 2021

Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.

Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.

Journal: Angewandte Chemie (International ed. in English)

Published: July 12, 2021

Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins.

Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins.

Journal: Journal of medicinal chemistry

Published: July 07, 2021

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.

Journal: Journal of medicinal chemistry

Published: August 14, 2020

GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family.

GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family.

Journal: ACS medicinal chemistry letters

Published: May 11, 2020

Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening.

Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening.

Journal: Journal of medicinal chemistry

Published: January 07, 2020

Cellular Target Engagement Approaches to Monitor Epigenetic Reader Domain Interactions.

Cellular Target Engagement Approaches to Monitor Epigenetic Reader Domain Interactions.

Journal: SLAS discovery : advancing life sciences R & D

Published: December 26, 2019

The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.

The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.

Journal: Journal of medicinal chemistry

Published: September 25, 2014

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.

Journal: Journal of medicinal chemistry

Published: September 11, 2013

Naphthyridines as novel BET family bromodomain inhibitors.

Naphthyridines as novel BET family bromodomain inhibitors.

Journal: ChemMedChem

Published: June 10, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026